SCHEMBL5144432

SCHEMBL5144432

CCCCn1c(-c2ccccc2)nc(-c2ccccc2)c1CN(CCC)Cc1ccc(OC)cc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
C5AR1 P21730 1/20 0.44
ALDH1A1 P00352 4/20 0.41
TSHR P16473 3/20 0.41
KDM4E B2RXH2 3/20 0.41
NPSR1 Q6W5P4 3/20 0.41
GAA P10253 2/20 0.41
LMNA P02545 2/20 0.41
BCHE P06276 4/20 0.41
DRD2 P14416 1/20 0.40
DRD3 P35462 1/20 0.40
SMPD1 P17405 1/20 0.40
HSD17B10 Q99714 1/20 0.39
SMN1; SMN2 Q16637 3/20 0.39
TP53 P04637 2/20 0.39
MAPT P10636 2/20 0.39
HTT P42858 2/20 0.39
CNR2 P34972 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
MEN1 O00255 1/20 0.39
CYP3A4 P08684 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5137164 0.96 C5AR1 (0.44) C5AR1ALDH1A1TSHRKDM4ENPSR1
SCHEMBL5135871 0.95 ATP4A (0.44) C5AR1ALDH1A1TSHRKDM4ENPSR1
SCHEMBL651365 0.95 C5AR1 (0.46) C5AR1ALDH1A1TSHRKDM4ENPSR1
SCHEMBL5072205 0.94 C5AR1 (0.46) C5AR1ALDH1A1TSHRKDM4ENPSR1
SCHEMBL5075063 0.93 TP53 (0.42) C5AR1ALDH1A1TSHRKDM4ENPSR1
SCHEMBL5136291 0.93 C5AR1 (0.45) C5AR1ALDH1A1TSHRKDM4ENPSR1
SCHEMBL5135687 0.93 C5AR1 (0.45) C5AR1ALDH1A1TSHRKDM4ENPSR1
SCHEMBL5136000 0.92 ATP4A (0.42) C5AR1ALDH1A1TSHRKDM4ENPSR1
SCHEMBL5136763 0.92 KDM4E (0.43) C5AR1ALDH1A1TSHRKDM4ENPSR1
SCHEMBL5134952 0.92 C5AR1 (0.44) C5AR1ALDH1A1TSHRKDM4ENPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1490044-A4 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORP (US) 2008-04-16 EP disclosed
EP-1490044-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2004-12-29 EP disclosed
WO-2003084524-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2003-10-16 WO disclosed